Celgene Corporation Continues to Get It Done
Celgene (NASDAQ: CELG) continues to grow revenue with its top-three drugs all experiencing sales growth of at least 20% year over year in the second quarter. The solid quarter allowed management to increase its 2017 earnings guidance.
Metric
Q2 2017
Source: Fool.com
Johnson & Johnson Stock
€135.46
-1.050%
With 32 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 196 € shows a positive potential of 44.69% compared to the current price of 135.46 € for Johnson & Johnson.
